EA201691847A1 - Способы снижения сердечно-сосудистого риска - Google Patents

Способы снижения сердечно-сосудистого риска

Info

Publication number
EA201691847A1
EA201691847A1 EA201691847A EA201691847A EA201691847A1 EA 201691847 A1 EA201691847 A1 EA 201691847A1 EA 201691847 A EA201691847 A EA 201691847A EA 201691847 A EA201691847 A EA 201691847A EA 201691847 A1 EA201691847 A1 EA 201691847A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cardiovascular risk
present
methods
statins
patients
Prior art date
Application number
EA201691847A
Other languages
English (en)
Other versions
EA039310B1 (ru
Inventor
Лоранс БЕССАК
Коринн Анотэн
Роберт К. Порди
Уилльям Дж. Сасьела
Грегори Г. Швартц
Филипп Габриель СТЕГ
Original Assignee
Санофи Байотекнолоджи
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи Байотекнолоджи, Ридженерон Фармасьютикалз, Инк. filed Critical Санофи Байотекнолоджи
Publication of EA201691847A1 publication Critical patent/EA201691847A1/ru
Publication of EA039310B1 publication Critical patent/EA039310B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение предусматривает способы лечения заболеваний и нарушений, которые связаны с повышенными уровнями липидов и липопротеинов. Способы по настоящему изобретению предусматривают введение пациенту с высоким сердечно-сосудистым риском фармацевтической композиции, содержащей ингибитор PCSK9. В определенных вариантах осуществления ингибитором PCSK9 является антитело к PCSK9, такое как иллюстративное антитело, обозначенное в данном документе как mAb316Р или алирокумаб. Способы по настоящему изобретению применимы для лечения пациентов с высоким сердечно-сосудистым риском, имеющих гиперхолестеролемию и повышенные уровни других атерогенных липопротеинов, которые резистентны к терапии посредством максимально переносимой дозы статинов. В частности, способы по настоящему изобретению применимы для снижения сердечно-сосудистого риска и понижения уровней атерогенных липопротеинов у пациентов с высоким сердечно-сосудистым риском в течение 12 месяцев после приступа острого коронарного синдрома, несмотря на терапию посредством максимально переносимой дозы статинов.
EA201691847A 2015-02-26 2015-03-13 Способы снижения сердечно-сосудистого риска EA039310B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305293 2015-02-26
PCT/US2015/020564 WO2015142668A1 (en) 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk

Publications (2)

Publication Number Publication Date
EA201691847A1 true EA201691847A1 (ru) 2017-01-30
EA039310B1 EA039310B1 (ru) 2022-01-12

Family

ID=52648962

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691847A EA039310B1 (ru) 2015-02-26 2015-03-13 Способы снижения сердечно-сосудистого риска

Country Status (11)

Country Link
US (2) US20150284473A1 (ru)
EP (1) EP3119810B1 (ru)
JP (2) JP2017509624A (ru)
KR (2) KR20160132459A (ru)
CN (3) CN106794244A (ru)
AU (2) AU2015231713B2 (ru)
CA (1) CA2942549A1 (ru)
EA (1) EA039310B1 (ru)
IL (1) IL304491A (ru)
MX (1) MX2016011975A (ru)
WO (1) WO2015142668A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2668212B1 (en) 2011-01-28 2018-03-21 Sanofi Biotechnology Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN111789944A (zh) 2011-09-16 2020-10-20 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
CN111920954A (zh) 2013-06-07 2020-11-13 再生元制药公司 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
EP3882273A1 (en) 2013-11-12 2021-09-22 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
CA2954767A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
EP3169362B1 (en) * 2014-07-16 2020-06-10 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia
US10472424B2 (en) 2014-09-23 2019-11-12 Pfizer Inc. Treatment with anti-PCSK9 antibodies
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Ltd peptídeo
AU2019231703A1 (en) * 2018-03-06 2020-10-22 Regeneron Pharmaceuticals, Inc. Use of PCSK9 inhibitor for reducing cardiovascular risk
CA3105071A1 (en) * 2018-07-02 2020-01-09 Abcentra, Llc Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis
WO2020037153A1 (en) * 2018-08-17 2020-02-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
US20230312750A1 (en) * 2019-11-18 2023-10-05 Ad Pharmaceuticals Co., Ltd. Anti-pcsk9 antibody and use thereof
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN114848849B (zh) * 2022-04-25 2023-11-17 南方科技大学 Pcsk9蛋白抑制剂在治疗心血管疾病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2668212B1 (en) * 2011-01-28 2018-03-21 Sanofi Biotechnology Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول

Also Published As

Publication number Publication date
MX2016011975A (es) 2016-12-05
CN106794244A (zh) 2017-05-31
US20150284473A1 (en) 2015-10-08
AU2021201118A1 (en) 2021-03-11
EA039310B1 (ru) 2022-01-12
EP3119810B1 (en) 2024-02-28
AU2015231713A1 (en) 2016-10-20
JP2017509624A (ja) 2017-04-06
WO2015142668A1 (en) 2015-09-24
KR20220157516A (ko) 2022-11-29
CN114558129A (zh) 2022-05-31
AU2015231713B2 (en) 2020-11-19
CA2942549A1 (en) 2015-09-24
KR20160132459A (ko) 2016-11-18
IL304491A (en) 2023-09-01
EP3119810C0 (en) 2024-02-28
EP3119810A1 (en) 2017-01-25
US20220144969A1 (en) 2022-05-12
CN114642661A (zh) 2022-06-21
JP2022141868A (ja) 2022-09-29

Similar Documents

Publication Publication Date Title
EA201691847A1 (ru) Способы снижения сердечно-сосудистого риска
MX2020009246A (es) Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
MX2018012741A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia familiar.
MX2018012221A (es) Metodos para tratar hiperlipidemia con un inhibidor de proteina tipo angiopoyetina 8 y un inhibidor de proteina tipo angiopoyetina 3.
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
PH12020500555A1 (en) Esketamine for the treatment of depression
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EA201690284A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
BR112015000808A2 (pt) regime de dosagem para inibidores de janus quinase (jak)
BR112022021381A2 (pt) Compostos para o tratamento de sars
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
BR112022023187A2 (pt) Compostos para o tratamento da sars
EA201491545A1 (ru) Способ лечения гиперхолестеринемии